Skip to main content
SpringerLink
Log in

Self-injectable SC abatacept available in Canada for RA

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bristol Myers Squibb Canada. CDR recommends self-injectable subcutaneous formulation of first non-anti-TNF biologic treatment available in both intravenous and subcutaneous formulations to be reimbursed for Canadians with moderately to severely active RA. Media Release : 12 Aug 2013. Available from: URL: http://www.bmscanada.ca.

  2. Government of Ontario's Ministry of Health Approval of the Reimbursement of Rituxan (Rituximab) for the Treatment of Pemphigus Vulgaris Announced. Media Release : 13 Aug 2013. Available from: URL: http://www.pemphigus.ca.

Download references

Additional information

* tumour necrosis factor

Rights and permissions

Reprints and permissions

About this article

Cite this article

Self-injectable SC abatacept available in Canada for RA. PharmacoEcon Outcomes News 685, 10 (2013). https://doi.org/10.1007/s40274-013-0659-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0659-0

Search

Navigation